WuXi Biologics (2269) Stock Price, Fundamentals & Analysis

What 2269 does

WuXi Biologics (2269) is a stock listed on the Hong Kong Stock Exchange in the Healthcare sector, specifically the Biotechnology industry. Headquartered in Wuxi, China, the company provides end-to-end solutions and services for biologics discovery, development, and manufacturing across multiple regions. It operates through two segments: Biologics and XDC, offering a suite of solutions for biologic discovery that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms.

Key numbers explained

• 53 HKD is the current price of WuXi Biologics (2269).
• The trailing P/E ratio of 38.1 shows how much investors pay per unit of recent earnings; a higher number often reflects growth expectations.
• The forward P/E ratio of 24.5 uses expected future earnings and is typically lower than the trailing P/E when growth is anticipated.
• Earnings per share, trailing 12 months of 1.39 CNY represents the portion of the company's profit allocated to each share over the last year.
• Dividend yield of 0% and 0% share of earnings paid out as dividends mean the company currently does not distribute cash to shareholders.
• Beta of 0.62 suggests the stock tends to be less volatile than the overall market.
• Price-to-book of 3.88 compares the market price to the company's book value per share.
• Debt-to-equity ratio of 5% indicates a low level of debt relative to shareholders' equity.

What to watch

Investors tracking WuXi Biologics (2269) often monitor the broader Healthcare sector and peers such as WuXi AppTec (2359), Hansoh Pharmaceutical Group (3692), and Sinopharm Group (1099). General factors that can affect this kind of stock include regulatory developments in biologics, changes in drug development pipelines, currency movements between CNY and HKD, and shifts in investor sentiment toward the biotechnology industry. The next earnings date is Aug 25, 2026, which is a key date for updated financial results.